Resource-based Center for the Advancement of Precision Medicine in Rheumatology
Project Number5P30AR070155-05
Contact PI/Project LeaderNAKAMURA, MARY C
Awardee OrganizationUNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Description
Abstract Text
PROJECT SUMMARY/ABSTRACT
The UCSF Resource-based Center for the Advancement of Precision Medicine in Rheumatology (P30)
will provide critically important resources and expertise to enable cutting-edge rheumatic disease research.
Given the emerging opportunities related to precision medicine, in conjunction with the significant
heterogeneity encompassed within the rheumatic diseases, our Center will focus on providing resources for
research that seeks to define underlying etiologic heterogeneity within and across rheumatic diseases by
applying new approaches and technology developed as part of the exciting field of precision medicine. UCSF
represents an ideal environment for the proposed P30 Center given tremendous institutional strengths in
immunology, genomics, molecular technologies, computational biology, and clinical research, including
engagement of at-risk populations and racial/ethnic minorities. In addition, UCSF is recognized as a leader in
clinical care of rheumatic disease patients across the age span, from childhood to old age. Further supporting
the rationale for investing in our Center are the substantial resources that can be leveraged at UCSF: sub-
specialty rheumatic disease clinics for lupus, rheumatoid arthritis, vasculitis, scleroderma, ankylosing
spondylitis, and pediatric rheumatic disease; the NIH-funded UCSF Multidisciplinary Clinical Research Center
(NIAMS P60) and Autoimmunity Center of Excellence (NIAID ACE); and the UCSF-Stanford Arthritis Center of
Excellence. To facilitate innovative and collaborative rheumatic disease research, our Center will include: 1) a
Human Subjects and Clinical Phenotyping Core co-directed by Drs. Patricia Katz and Jinoos Yazdany,
which will provide centralized coordination of subject recruitment, clinical phenotyping, and clinical data
collection and management (e.g., for electronic health record data, and patient or physician reported
outcomes); 2) a Genomics and Molecular Resources Core, co-directed by Drs. Pui-Yan Kwok and Lindsey
Criswell, which will provide centralized biospecimen processing and storage to facilitate access for more
researchers and provide consultation and coordination related to acquisition of genomics and molecular
phenotyping services; 3) an Integrative Bioinformatics Core, co-directed by Drs. Atul Butte and Marina
Sirota, which will provide computational and analytical expertise for study design, bioinformatics analysis of
clinical and molecular data, data integration and data dissemination; and 4) an Administrative Core directed
by Dr. Lindsey Criswell, with Dr. Mary Nakamura as associate director, which includes an enrichment program
designed to attract and support both young and experienced investigators through provision of pilot grants, a
mentoring program, educational seminars, and an annual symposium. These resources will meet the stated
needs of our research community and will have a major impact on advancing precision medicine research in
rheumatology by providing access to research infrastructure and consultation, biospecimens with defined
clinical data, and cutting-edge genomics, molecular, and computational biology tools.
Public Health Relevance Statement
PROJECT NARRATIVE
The UCSF Resource-based Center for the Advancement of Precision Medicine in Rheumatology will provide
investigators with access to resources, expertise, training and pilot funding to capitalize on new technologies
and opportunities in precision medicine. The Center will bring together teams of scientists to study ways to
better define disease subgroups that may have different etiologies, prognosis, or treatment responses. By
providing Core resources to access clinical data and biospecimens along with new technologies for molecular
phenotyping and bioinformatics analyses, our Center aims to improve approaches to the diagnosis and
treatment of rheumatic disease.
NIH Spending Category
No NIH Spending Category available.
Project Terms
ARHGEF5 geneAddressAgeAnkylosing spondylitisArthritisAutoimmunityBehavioralBig DataBioinformaticsBiomedical ResearchCaliforniaChildhoodClinicClinicalClinical DataClinical InformaticsClinical ResearchCollaborationsCommunitiesComputational BiologyConsultationsDataData AnalysesData CollectionDatabase and Analysis PortalDevelopmentDiagnosisDiseaseElectronic Health RecordEnvironmentEtiologyFosteringFundingGeneticGenomicsGoalsGrantHealthHeterogeneityImmunologyLaboratory ResearchLeadershipLongevityLupusMentorsMolecularMolecular BiologyMonitorNational Institute of Allergy and Infectious DiseaseNational Institute of Arthritis and Musculoskeletal and Skin DiseasesNational Research CouncilOutcomePatient RecruitmentsPatientsPhysiciansPlayPopulations at RiskPreventionReportingResearchResearch DesignResearch EthicsResearch InfrastructureResearch PersonnelResourcesRheumatismRheumatoid ArthritisRheumatologyRoleSan FranciscoScientistSclerodermaSecureSelection for TreatmentsSeriesServicesTechnologyTrainingUnited States National Institutes of HealthUniversitiesVasculitisVisionaccurate diagnosisbaseclinical careclinical phenotypedata disseminationdata integrationdata managementdata warehousedesigndisease diagnosisdisorder subtypeethnic minority populationexperiencegenomic datahuman datahuman subjectimprovedinnovationmedical specialtiesmolecular phenotypemultidisciplinarynew technologynovel strategiesnovel therapeuticsoutcome forecastpediatric rheumatic diseasesphenotypic dataprecision medicineprogramsracial and ethnicranpirnaserecruitresearch studysymposiumtooltreatment response
National Institute of Arthritis and Musculoskeletal and Skin Diseases
CFDA Code
846
DUNS Number
094878337
UEI
KMH5K9V7S518
Project Start Date
21-September-2016
Project End Date
31-August-2021
Budget Start Date
01-September-2020
Budget End Date
31-August-2021
Project Funding Information for 2020
Total Funding
$721,693
Direct Costs
$586,391
Indirect Costs
$343,038
Year
Funding IC
FY Total Cost by IC
2020
National Institute of Arthritis and Musculoskeletal and Skin Diseases
$721,693
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5P30AR070155-05
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P30AR070155-05
Patents
No Patents information available for 5P30AR070155-05
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P30AR070155-05
Clinical Studies
No Clinical Studies information available for 5P30AR070155-05
News and More
Related News Releases
No news release information available for 5P30AR070155-05
History
No Historical information available for 5P30AR070155-05
Similar Projects
No Similar Projects information available for 5P30AR070155-05